Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q2 2019 · 10-Q
Revenue$0.00$0.00no prior Q2 2018 on file Net Income-$632.69K-$632.69KN/M vs Q2 2018 EPS Diluted$0.00$0.00— vs Q2 2018 Operating Income-$635,500N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
derived
ended Jun 30, 2019 · filed Aug 12, 2019 · 43 d after period end